SCHEMBL21270577

SCHEMBL21270577

CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cccnc2)no1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ TSHR P16473 2/20 0.50
▸ HTT P42858 4/20 0.44
▸ MAPT P10636 3/20 0.44
▸ LMNA P02545 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTR1A P08908 2/20 0.44
▸ DRD2 P14416 2/20 0.44
▸ HTR2A P28223 2/20 0.44
▸ KCNH2 Q12809 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ SMPD1 P17405 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21270580 1.00 ALDH1A1 (0.50) ALDH1A1TSHRHTTMAPTLMNA
SCHEMBL23375208 0.90 HTT (0.48) ALDH1A1TSHRHTTLMNASMN1; SMN2
SCHEMBL21270181 0.89 HTT (0.43) ALDH1A1TSHRHTTMAPTLMNA
SCHEMBL21270179 0.89 HTT (0.43) ALDH1A1TSHRHTTMAPTLMNA
SCHEMBL21270908 0.88 BDKRB1 (0.51) ALDH1A1TSHRHTTNPSR1SMPD1
SCHEMBL21270905 0.88 BDKRB1 (0.51) ALDH1A1TSHRHTTNPSR1SMPD1
SCHEMBL21270445 0.88 SMPD1 (0.46) ALDH1A1TSHRHTTLMNAMEN1
SCHEMBL21270449 0.88 SMPD1 (0.46) ALDH1A1TSHRHTTLMNAMEN1
SCHEMBL21270788 0.88 ALDH1A1 (0.45) ALDH1A1TSHRHTTLMNANPSR1
SCHEMBL21270802 0.88 ALDH1A1 (0.43) ALDH1A1TSHRHTTNPSR1SMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US claimed
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-11472796-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-10-18 — — US disclosed
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-05-20 — — US disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-11472796-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback